Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2556316 | 0.82 | JAK2 (0.43) | MAPT | |
| SCHEMBL29463867 | 0.75 | P2RX7 (0.44) | PGK1PGK2 | |
| SCHEMBL415739 | 0.75 | P2RX7 (0.44) | PGK1PGK2 | |
| SCHEMBL2565469 | 0.73 | MAPT (0.35) | PGK1PGK2CYP3A4TSHRMAPT | |
| SCHEMBL16472119 | 0.73 | MAPT (0.35) | PGK1PGK2CYP3A4TSHRMAPT | |
| SCHEMBL17184335 | 0.73 | CYP3A4 (0.58) | PGK1PGK2CYP3A4TSHRMAPT | |
| SCHEMBL10749077 | 0.71 | CYP3A4 (0.40) | PGK1PGK2CYP3A4TSHRMAPT | |
| SCHEMBL29168104 | 0.70 | IRAK4 (0.33) | PGK1PGK2CYP3A4TSHRMAPT | |
| SCHEMBL116643 | 0.69 | — | — | |
| SCHEMBL30259849 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709533-B2 | Imines as ion channel modulators | ICAGEN, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1861356-A1 | IMINES AS ION CHANNEL MODULATORS | Icagen, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| US-20060178346-A1 | Imines as ion channel modulators | ICAGEN, INC. (US) | 2006-08-10 | — | — | US | disclosed |
| WO-2006084031-A1 | IMINES AS ION CHANNEL MODULATORS | ICAGEN, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178346-A1 | Imines as ion channel modulators | KCNN1, KCNN3, KCNN2 | PGK1 386/4885PGK2 474/4885CYP3A4 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.